Nanette Schlattermund, Senior Business Development Manager at IDT (fourth from the left), is participating in a roundtable discussion during the 2025 BPI Europe event program. Photo by IDT Biologica
IDT Biologica (IDT), a subsidiary of SK bioscience and a leading German CDMO (Contract Development and Manufacturing Organization), has been actively participating in major global bio events, strengthening its position as a global CDMO and accelerating efforts to secure new contracts.
IDT participated in the BioProcess International Europe (BPI Europe) event, held from May 12 to May 15, 2025 (local time), at the Congress Center Hamburg (CCH) in Hamburg, Germany. BPI is a globally renowned bio industry conference that discusses the latest technologies and partnerships across all processes of biopharmaceutical development, production, and analysis. It is held annually in the United States, Europe, and Asia.
During the four-day event, IDT showcased its customized end-to-end service capabilities, spanning from the development to manufacturing of viral vaccines, gene and immunotherapies, and aseptic injectables, as well as various partnership case studies.
In particular, Federico Pollano, Chief Commercial Officer (CCO), and Nanette Schlattermund, Senior Business Development Manager, attended the event in person to discuss opportunities for next-generation biopharmaceutical development and production with potential partners.
Prior to this, in March and April, IDT also participated in large-scale global pharmaceutical, bio, and vaccine events, sharing the latest market trends and technological developments, and expanding its global business through networking with industry stakeholders.
In March, IDT sought business opportunities by participating in DCAT (Drug·Chemical & Associated Technologies) Week 2025, held in New York, USA. DCAT Week, which began in 1890 under the auspices of the New York Chamber of Commerce, is a high-level business networking event for global pharmaceutical and bio companies.
IDT set up a dedicated meeting room attended by senior executives including Sally Choi, Co-CEO of IDT, Federico Pollano, Chief Commercial Officer (CCO), and Lifeng He, Global Head of Business Development, to discuss strategic partnerships and potential business opportunities with key industry figures.
Last month, IDT also participated in The World Vaccine Congress 2025, held at the Walter E. Washington Convention Center in Washington, D.C., USA, where it actively promoted its CDMO capabilities and technology platforms through exchanges with global vaccine experts and public health officials. Notably, during the corporate presentation session, IDT drew attention by sharing its successful scale-up experiences of vaccines and cell and gene therapies (CGT) using the industrial-scale bioreactor 'iCELLis 500', which enhances the efficiency of cell processing and virus production.
IDT is also scheduled to continue its global business activities by participating in the BIO International Convention (BIO USA), the world's largest bio industry event, to be held in Boston, USA, from June 16 to June 19, 2025.
Meanwhile, IDT, whose acquisition process was successfully completed in October 2024, has over 100 years of business history and serves multinational pharmaceutical companies and government agencies in North America, Europe, and Asia as clients. IDT has contributed to the earnings stability of SK bioscience by posting profits in the first quarter of this year, following a profitable fourth quarter last year. The company plans to continue improving facility operation efficiency and expanding contract orders, aiming to surpass annual sales of KRW 410 billion and achieve a turnaround to profitability this year.
Sally Choi, Co-CEO of IDT, stated, "IDT has been recognized for its outstanding technological capabilities, reliability, and customer satisfaction, as evidenced by being selected as the winner in the international category for biologics at the 2025 CDMO Leadership Awards, which are directly evaluated by global pharmaceutical and bio companies. Moving forward, we will accelerate our global business expansion based on IDT's differentiated, customer-tailored services and extensive global partnership experience."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
